MedPath

Lopinavir

Generic Name
Lopinavir
Brand Names
Kaletra
Drug Type
Small Molecule
Chemical Formula
C37H48N4O5
CAS Number
192725-17-0
Unique Ingredient Identifier
2494G1JF75
Background

Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. saquinavir, nelfinavir), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the HIV-1 protease.

Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.

Indication

用于高效抗逆转录病毒疗法（HAART）的组成药物。

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Phase 4
Recruiting
Conditions
HIV-1-infection
Interventions
Drug: F/TAF (High Dose Tablet)
Drug: B/F/TAF (Low Dose)
Drug: E/C/F/TAF (Low Dose)
Drug: F/TAF (Low Dose Tablet)
Drug: F/TAF (Lowest Dose Tablet)
Drug: F/TAF (High Dose TOS)
Drug: B/F/TAF (High Dose)
Drug: F/TAF (Low Dose TOS)
Drug: B/F/TAF (Lowest Dose TOS)
Drug: F/TAF (Lowest Dose TOS)
Drug: B/F/TAF (High Dose TOS)
Drug: 3rd ARV Agent
Drug: B/F/TAF (Low Dose TOS)
Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Drug: ATV
Drug: DRV
First Posted Date
2024-03-29
Last Posted Date
2025-05-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
350
Registration Number
NCT06337032
Locations
🇿🇼

University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe

🇦🇷

Helios Salud, Buenos Aires, Argentina

🇿🇦

Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa

and more 9 locations

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients

Phase 1
Recruiting
Conditions
COVID-19
Hospitalized COVID-19 Patients
Interventions
Other: Corticosteroid Therapy-enhanced Standard Care (CTSC)
First Posted Date
2023-06-29
Last Posted Date
2024-02-06
Lead Sponsor
Lebanese University
Target Recruit Count
1000
Registration Number
NCT05925140
Locations
🇱🇧

Lebanese University, Tripoli, Lebanon

🇱🇧

SZUMC, Zgharta, North, Lebanon

Lopinavir/Ritonavir in PLWH With High-Grade AIN

Phase 1
Recruiting
Conditions
High-Grade Anal Intraepithelial Neoplasia
Interventions
First Posted Date
2022-04-19
Last Posted Date
2025-05-15
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
21
Registration Number
NCT05334004
Locations
🇺🇸

UW Digestive Health Center Anoscopy Clinic, Madison, Wisconsin, United States

Public Health Emergency: SOLIDARITY TRIAL Philippines

First Posted Date
2021-08-27
Last Posted Date
2022-03-02
Lead Sponsor
University of the Philippines
Target Recruit Count
1314
Registration Number
NCT05024006
Locations
🇵🇭

Chinese General Hospital, Manila, Metro Manila, Philippines

🇵🇭

UP - Philippine General Hospital, Manila, Metro Manila, Philippines

🇵🇭

San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines

and more 22 locations

A Study of Combination Therapies to Treat COVID-19 Infection

Phase 2
Withdrawn
Conditions
SARS Pneumonia
Corona Virus Infection
Coronavirus Infection
Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
Coronavirus-19
COVID
SARS-CoV 2
COVID-19
Interventions
First Posted Date
2020-07-07
Last Posted Date
2021-04-08
Lead Sponsor
ProgenaBiome
Registration Number
NCT04459702
Locations
🇺🇸

ProgenaBiome, Ventura, California, United States

Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

Not Applicable
Completed
Conditions
Hydroxychloroquine
COVID-19
Favipiravir
Kaletra
Lopinavir/Ritonavir
Interventions
First Posted Date
2020-05-06
Last Posted Date
2020-06-16
Lead Sponsor
Baqiyatallah Medical Sciences University
Target Recruit Count
40
Registration Number
NCT04376814
Locations
🇮🇷

Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of

OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome

First Posted Date
2020-04-28
Last Posted Date
2021-04-27
Lead Sponsor
Fondation Hôpital Saint-Joseph
Registration Number
NCT04365582

Treatment for COVID-19 in High-Risk Adult Outpatients

First Posted Date
2020-04-21
Last Posted Date
2022-08-08
Lead Sponsor
University of Washington
Target Recruit Count
289
Registration Number
NCT04354428
Locations
🇺🇸

SUNY Upstate Medical University, Syracuse, New York, United States

🇺🇸

Tulane University, New Orleans, Louisiana, United States

🇺🇸

University of Washington Coordinating Center, Seattle, Washington, United States

and more 3 locations

Umifenovir in Hospitalized COVID-19 Patients

Phase 4
Conditions
COVID-19
Interventions
Drug: Interferon-β 1a
Drug: Standards of Care
First Posted Date
2020-04-17
Last Posted Date
2020-04-20
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
40
Registration Number
NCT04350684
Locations
🇮🇷

Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of

Interferon Beta 1a in Hospitalized COVID-19 Patients

First Posted Date
2020-04-17
Last Posted Date
2020-04-20
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
40
Registration Number
NCT04350671
Locations
🇮🇷

Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy